复方大黄制剂在糖尿病肾病患者中的应用观察  

Application of the Fufang Dahuang preparation in treating diabetic nephropathy

作　　者：董晓光[1] 赵旭涛[1] 

机构地区：[1]济南市中医医院,山东济南250012

出　　处：《中医临床研究》2016年第32期62-64,共3页Clinical Journal Of Chinese Medicine

摘　　要：目的:观察复方大黄制剂在糖尿病肾病患者中的应用效果。方法:选取我院收治的糖尿病肾病患者72例,采取数字随机法分成观察组(n=36)和对照组(n=36)。对照组采取常规治疗,观察组在对照组基础上采取复方大黄制剂治疗,比较两组临床效果。结果:观察组治疗后Cr、UAER水平均低于对照组,差异有统计学意义(P<0.05)。观察组治疗后收缩压水平高于对照组,差异有统计学意义(P<0.05)。观察组治疗后Cr、UAER水平均低于治疗前,差异有统计学意义(P<0.05)。观察组治疗后收缩压水平高于治疗前,差异有统计学意义(P<0.05)。观察组与对照组用药不良反应发生率分别为5.56%、2.78%,两组用药不良反应发生率比较,差异无统计学意义(P>0.05)。结论:复方大黄制剂在糖尿病肾病患者中的应用效果显著,并且用药安全,是有效的治疗方案之一。Objective: To observe effects of the Fufang Dahuang preparation on diabetic nephropathy. Methods: 72 patients with diabetic nephropathy were randomly divided into the observation group (n=36) and control group (n=36). The control group was treated by routine therapy, and the treatment group took the Fufang Dahuang preparation more. Results:After treatment, the levels of Cr and UAER in the observation group were lower than those in the control group (P<0.05). The level of systolic blood pressure in the observation group was higher than that in the control group (P<0.05). The levels of Cr and UAER in the observation group were lower than those before treatment (P<0.05). The level of systolic blood pressure in the observation group was higher than that before treatment (P<0.05). The incidence of ADRs in the observation group and the control group was 5.56% and 2.78% respectively (P>0.05). Conclusion: The Fufang Dahuang preparation is effective and safe on diabetic nephropathy.

关 键 词：复方大黄制剂 糖尿病肾病 应用效果 

分 类 号：R587.1[医药卫生—内分泌]